Haemonetics Stock Performance
| HAE Stock | USD 48.17 0.50 1.05% |
The company retains a Market Volatility (i.e., Beta) of -0.77, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Haemonetics are expected to decrease at a much lower rate. During the bear market, Haemonetics is likely to outperform the market. At this point, Haemonetics has a negative expected return of -0.66%. Please make sure to check out Haemonetics' standard deviation, maximum drawdown, kurtosis, as well as the relationship between the total risk alpha and potential upside , to decide if Haemonetics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Haemonetics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in October 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return (0.10) | Five Day Return (4.84) | Year To Date Return (38.62) | Ten Year Return 43.64 | All Time Return 710.44 |
Last Split Factor 2:1 | Last Split Date 2012-12-03 |
1 | Acquisition by Robert Abernathy of 2693 shares of Haemonetics subject to Rule 16b-3 | 07/24/2025 |
2 | Analysts Estimate Haemonetics to Report a Decline in Earnings What to Look Out for | 07/31/2025 |
3 | Haemonetics 1st Quarter Fiscal Year 2026 Earnings Release Available on Investor Relations Website | 08/07/2025 |
4 | Does Haemonetics Revenue Decline Guidance Reveal Deeper Challenges in Its Transformation Strategy | 08/18/2025 |
5 | Does Haemonetics Corporation show high probability of rebound - Short Setup Accurate EntryExit Alerts - Newser | 09/05/2025 |
6 | Medical Devices Supplies - Specialty Stocks Q2 Earnings STAAR Surgical Firing on All Cylinders | 09/15/2025 |
7 | Disposition of 238 shares by Laurie Miller of Haemonetics at 49.95 subject to Rule 16b-3 | 09/17/2025 |
8 | Haemonetics Corporation Launches PerQseal Elite, Advancing Minimally Invasive Vascular Care | 09/18/2025 |
9 | 9 Analysts Have This To Say About Haemonetics | 09/23/2025 |
10 | Bausch Lomb, Enovis, and Haemonetics Shares Plummet, What You Need To Know | 09/25/2025 |
11 | Barrington Research Reiterates Outperform Rating for Haemonetics | 09/26/2025 |
| Begin Period Cash Flow | 178.8 M | |
| Total Cashflows From Investing Activities | -161.9 M |
Haemonetics | Build AI portfolio with Haemonetics Stock |
Haemonetics Relative Risk vs. Return Landscape
If you would invest 7,624 in Haemonetics on July 2, 2025 and sell it today you would lose (2,807) from holding Haemonetics or give up 36.82% of portfolio value over 90 days. Haemonetics is generating negative expected returns assuming volatility of 3.7861% on return distribution over 90 days investment horizon. In other words, 33% of stocks are less volatile than Haemonetics, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Haemonetics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Haemonetics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Haemonetics, and traders can use it to determine the average amount a Haemonetics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.173
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | HAE |
Estimated Market Risk
| 3.79 actual daily | 33 67% of assets are more volatile |
Expected Return
| -0.66 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.17 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Haemonetics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Haemonetics by adding Haemonetics to a well-diversified portfolio.
Haemonetics Fundamentals Growth
Haemonetics Stock prices reflect investors' perceptions of the future prospects and financial health of Haemonetics, and Haemonetics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Haemonetics Stock performance.
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.0652 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 3.25 B | ||||
| Shares Outstanding | 48.18 M | ||||
| Price To Earning | 50.35 X | ||||
| Price To Book | 2.63 X | ||||
| Price To Sales | 1.72 X | ||||
| Revenue | 1.36 B | ||||
| Gross Profit | 791.12 M | ||||
| EBITDA | 337.4 M | ||||
| Net Income | 167.68 M | ||||
| Cash And Equivalents | 306.76 M | ||||
| Cash Per Share | 4.79 X | ||||
| Total Debt | 1.22 B | ||||
| Debt To Equity | 1.12 % | ||||
| Current Ratio | 2.73 X | ||||
| Book Value Per Share | 18.32 X | ||||
| Cash Flow From Operations | 181.72 M | ||||
| Earnings Per Share | 3.27 X | ||||
| Market Capitalization | 2.32 B | ||||
| Total Asset | 2.45 B | ||||
| Retained Earnings | 352.17 M | ||||
| Working Capital | 356.86 M | ||||
| Current Asset | 488.09 M | ||||
| Current Liabilities | 185.55 M | ||||
About Haemonetics Performance
By analyzing Haemonetics' fundamental ratios, stakeholders can gain valuable insights into Haemonetics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Haemonetics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Haemonetics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 217.82 | 119.29 | |
| Return On Tangible Assets | 0.12 | 0.05 | |
| Return On Capital Employed | 0.12 | 0.07 | |
| Return On Assets | 0.07 | 0.04 | |
| Return On Equity | 0.20 | 0.06 |
Things to note about Haemonetics performance evaluation
Checking the ongoing alerts about Haemonetics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Haemonetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Haemonetics generated a negative expected return over the last 90 days | |
| Haemonetics has high historical volatility and very poor performance | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Barrington Research Reiterates Outperform Rating for Haemonetics |
- Analyzing Haemonetics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Haemonetics' stock is overvalued or undervalued compared to its peers.
- Examining Haemonetics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Haemonetics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Haemonetics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Haemonetics' stock. These opinions can provide insight into Haemonetics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Haemonetics Stock analysis
When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |